Peter Thiel
How Eli Lilly Validates the Peter Thiel Blueprint
We assume major pharmaceutical companies only acquire safe, traditional chemical compounds. Eli Lilly just dropped nearly four billion dollars on a Peter Thiel-backed psychedelics maker, proving that the smartest venture capital targets heavily regulated taboos before the mainstream catches on.
